Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICT-004: GLS-010 injection plus platinum-based chemotherapy ± bevacizumab as first-line treatment for persistent, recurrent or metastatic cervical cancer
CTR20230235Phase 3Active
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zimberelimab in Cervical Cancer (CC), sponsored by Guangzhou Gloria Biosciences Co., Ltd.. Started Apr 2023; status: active.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20230235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230235.